People · Operator
Named in public records as an officer, director or promoter · active 2013–2017 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| eGenesis, Inc. | — | Biotechnology | Series D+ | $265.0M | $316.4M | 2017 |
| Editas Medicine, Inc. | — | Biotechnology | Series D+ | $120.0M | $4.9B | 2015 |
| BlueTalon, Inc. | — | Other Technology | Series B | $25.9M | $486.6M | 2013 |
Boris Nikolic at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Boris Nikolic on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Kevin Bitterman | 1 | 15 |
| Matt Ocko | 1 | 13 |
| Scott Barclay | 1 | 8 |
| PAUL SEKHRI | 1 | 7 |
| Alexis Borisy | 1 | 6 |
| Brad Smith | 1 | 6 |
| Lucio Iannone | 1 | 6 |
| Bob More | 1 | 6 |
| Andrew Hack | 1 | 5 |
| Geoff MacKay | 1 | 5 |
| Douglas Cole | 1 | 5 |
| Julie Sunderland | 1 | 5 |
| Isaac Ciechanover | 1 | 5 |
| Matthew Kinsella | 1 | 4 |
| Katrine Bosley | 1 | 4 |
| Alexandra Glucksmann | 1 | 4 |
| Ed Cluss | 1 | 4 |
| Rahul Kakkar | 1 | 3 |
| Vic Myer | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.